Atigotatug Biosimilar – Anti-Fucosyl-GM1 mAb – Research Grade

Description of Atigotatug Biosimilar - Anti-Fucosyl-GM1 mAb - Research Grade

Introduction to Atigotatug Biosimilar – Anti-Fucosyl-GM1 mAb

Atigotatug Biosimilar – Anti-Fucosyl-GM1 mAb is a therapeutic antibody that has been developed as a biosimilar to the anti-Fucosyl-GM1 monoclonal antibody (mAb). This biosimilar is a research grade product that has been designed to target a specific therapeutic target, Fucosyl-GM1, and has shown promising results in preclinical studies.

Structure of Atigotatug Biosimilar – Anti-Fucosyl-GM1 mAb

Atigotatug Biosimilar – Anti-Fucosyl-GM1 mAb is a monoclonal antibody that is produced through recombinant DNA technology. It is a humanized IgG1 antibody, meaning that it has been engineered to have a human constant region while retaining the antigen-binding region of the original anti-Fucosyl-GM1 mAb. This structure allows for better compatibility and reduced immunogenicity in human patients.

The antibody has a molecular weight of approximately 150 kDa and consists of two heavy chains and two light chains. The heavy chains are composed of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains consist of one constant domain (CL) and one variable domain (VL). The variable domains are responsible for binding to the specific target, Fucosyl-GM1.

Activity of Atigotatug Biosimilar – Anti-Fucosyl-GM1 mAb

The primary activity of Atigotatug Biosimilar – Anti-Fucosyl-GM1 mAb is its ability to bind to the Fucosyl-GM1 antigen. Fucosyl-GM1 is a glycolipid that is expressed on the surface of certain cancer cells, including small cell lung cancer and neuroblastoma. The overexpression of Fucosyl-GM1 has been associated with increased tumor growth and metastasis, making it a promising therapeutic target.

By binding to Fucosyl-GM1, Atigotatug Biosimilar – Anti-Fucosyl-GM1 mAb can inhibit the growth and survival of cancer cells. This is achieved through several mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct cell death induction. These activities make Atigotatug Biosimilar – Anti-Fucosyl-GM1 mAb a potent therapeutic agent for the treatment of Fucosyl-GM1-expressing cancers.

Application of Atigotatug Biosimilar – Anti-Fucosyl-GM1 mAb

Atigotatug Biosimilar – Anti-Fucosyl-GM1 mAb is currently being studied for its potential use in the treatment of small cell lung cancer and neuroblastoma. Preclinical studies have shown promising results, with the antibody demonstrating strong anti-tumor activity and minimal toxicity.

In addition to its potential as a therapeutic agent, Atigotatug Biosimilar – Anti-Fucosyl-GM1 mAb can also be used in research settings to study the role of Fucosyl-GM1 in cancer development and progression. The biosimilar form of the antibody allows for more affordable and accessible research options, making it a valuable tool for scientists and researchers.

Conclusion

In summary, Atigotatug Biosimilar – Anti-Fucosyl-GM1 mAb is a promising therapeutic antibody that has been developed as a biosimilar to the anti-Fucosyl-GM1 mAb. Its structure, activity, and application make it a valuable tool in the fight against Fucosyl-GM1-expressing cancers. With further research and clinical trials, this biosimilar